Renaissance Technologies’s Taysha Gene Therapies TSHA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
Sell
-413,203
Closed -$1.85M 3619
2026
Q1
$1.85M Buy
413,203
+242,103
+141% +$1.13M ﹤0.01% 1943
2025
Q4
$941K Buy
+171,100
New +$831K ﹤0.01% 2318
2025
Q3
Sell
-54,900
Closed -$127K 3934
2025
Q2
$127K Buy
+54,900
New +$119K ﹤0.01% 3262
2025
Q1
Sell
-878,448
Closed -$1.52M 3846
2024
Q4
$1.52M Buy
+878,448
New +$1.82M ﹤0.01% 2226
2024
Q3
Sell
-41,100
Closed -$92.1K 3899
2024
Q2
$92.1K Sell
41,100
-287,400
-87% -$836K ﹤0.01% 3198
2024
Q1
$943K Sell
328,500
-768,900
-70% -$1.6M ﹤0.01% 2525
2023
Q4
$1.94M Buy
1,097,400
+499,400
+84% +$996K ﹤0.01% 1962
2023
Q3
$1.89M Buy
598,000
+373,600
+166% +$698K ﹤0.01% 1903
2023
Q2
$148K Sell
224,400
-25,200
-10% -$18.2K ﹤0.01% 3363
2023
Q1
$199K Sell
249,600
-270,200
-52% -$349K ﹤0.01% 3288
2022
Q4
$1.18M Buy
519,800
+101,300
+24% +$205K ﹤0.01% 2435
2022
Q3
$808K Sell
418,500
-105,100
-20% -$382K ﹤0.01% 2627
2022
Q2
$1.95M Buy
523,600
+273,100
+109% +$1.08M ﹤0.01% 2212
2022
Q1
$1.63M Buy
+250,500
New +$1.87M ﹤0.01% 2381

Other funds holding TSHA

Renaissance Technologies's TSHA Position: Q2 2026 in Review

Renaissance Technologies sold out of Taysha Gene Therapies (TSHA) in Q2 2026, closing a stake of 413,203 shares — an estimated $1.85M sold.

Renaissance Technologies first reported a position in TSHA in Q1 2022 and held it in 14 quarters. The position peaked at $1.95M in Q2 2022. 208 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • Renaissance Technologies reported no remaining Taysha Gene Therapies position as of Q2 2026 after selling out during the quarter.
  • Renaissance Technologies sold 413,203 Taysha Gene Therapies shares in Q2 2026, an estimated $1.85M.
  • Renaissance Technologies first reported a position in Taysha Gene Therapies in Q1 2022 and held it in 14 quarters.
  • Renaissance Technologies's Taysha Gene Therapies position peaked at $1.95M in Q2 2022.
  • 208 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on Renaissance Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.